A review of methods for futility stopping based on conditional power.
about
Personalized medicine using DNA biomarkers: a reviewA new futility test approach in clinical interim data monitoring.Design of a prospective clinical study on the agreement between the Continuous GlucoseMonitor, a novel device for CONTinuous ASSessment of blood GLUcose levels, and the RAPIDLab® 1265 blood gas analyser: The CONTASSGLU study.An adaptive alpha spending algorithm improves the power of statistical inference in microarray data analysis.Adapting by calibration the sample size of a phase III trial on the basis of phase II data.A randomized trial of weekly symptom telemonitoring in advanced lung cancerRandomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.A threshold sample-enrichment approach in a clinical trial with heterogeneous subpopulations.Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial.Standardized preoperative corticosteroid treatment in neonates undergoing cardiac surgery: results from a randomized trialUse of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial.Application of futility analysis to refine jitter recordings in myasthenia gravisLuteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer.Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the Carotid Occlusion Surgery Study randomized trial.Cost-effectiveness and quality of life in surgeon versus general practitioner-organised colon cancer surveillance: a randomised controlled trial.High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trialHomocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial.A Placebo-Controlled, Prospective, Randomized Clinical Trial of Polyethylene Glycol and Methylprednisolone Sodium Succinate in Dogs with Intervertebral Disk Herniation.Non-invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA(3)CT): Design of a Phase IIb, placebo-controlled, double-blind, randomized clinical trial of doxycycline for the reduction of growth of small abdominal aortic aneurysm.Effect of Cranberry Extract on the Frequency of Bacteriuria in Dogs with Acute Thoracolumbar Disk Herniation: A Randomized Controlled Clinical Trial.Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility.Continuously updated network meta-analysis and statistical monitoring for timely decision-making.The conditional power of randomization tests for single-case effect sizes in designs with randomized treatment order: A Monte Carlo simulation study.Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints.Comparison of futility monitoring guidelines using completed phase III oncology trials.Choice of futility boundaries for group sequential designs with two endpoints.Interim analysis based on the weighted log-rank test for delayed treatment effects under staggered patient entry.Optimal two-stage log-rank test for randomized phase II clinical trialsBayesian decision theoretic two-stage design in phase II clinical trials with survival endpointThe type II error probability of a group sequential test of efficacy and futility, and considerations for power and sample size.Weight regain after slimming induced by an energy-restricted diet depends on interleukin-6 and peroxisome-proliferator-activated-receptor-gamma2 gene polymorphisms.Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.Efficacy and safety of the glycine transporter-1 inhibitor org 25935 for the prevention of relapse in alcohol-dependent patients: a randomized, double-blind, placebo-controlled trial.Alternative views on setting clinical trial futility criteria.Exploratory trials in mental health: anything to learn from other disciplines?A model-based conditional power assessment for decision making in randomized controlled trial studies.Futility for subgroup analyses in the adaptive signature design.Epigenetic patterns of two gene promoters (TNF-α and PON) in stroke considering obesity condition and dietary intake.Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
P2860
Q27022319-001DB87F-3D7F-48E5-A4A0-DAEEE254BB56Q30570910-A152DB8F-1757-4725-9D6C-AB8A892CB001Q31097763-F613E458-31C7-43F6-8527-C5A486B4A73BQ33289174-368B36C0-7D4C-4BF1-8C43-929F47F1A023Q33530189-67FC276D-B83B-4646-8E9E-665791354187Q33579085-ECDE7C8B-62C3-41F6-8B36-B6C25F7DB172Q34106830-078A903C-73F8-4DEB-94AC-7AF027A28461Q34370382-8B0AB216-DD0C-49D3-A9C0-1E16A5332B4DQ34403869-E38A7E0E-F28A-46BE-B014-55925DABAC6CQ35179433-57711550-73F3-4A05-BE56-556738FE2F8CQ35782141-0F922BE4-2966-4C13-93A7-1340AE72A5F9Q35855015-62518279-E941-481F-8912-0F1343834535Q35997372-1CBF11CE-7195-4064-A715-8CD51F926080Q36697448-2458FC49-9DD0-44FE-B7B5-91721D834FA6Q36809974-5854DBD9-7D67-42EB-8646-B2010FD89826Q36838747-7611CCF5-ABF3-4529-BE70-A594E4492C69Q36953576-98DB61E0-50DC-48F1-847F-0FD18C377555Q37020466-8DA7A8CF-AD18-4B34-89A1-B4B62407C51AQ37135570-5742D359-250C-490B-9FB3-2D0E1A6FB905Q37601856-C14F76D7-535E-49B0-9543-948B7AE96991Q37637577-F877E152-B5DE-4683-9BE5-87C1EB922535Q38759291-F84D3BAA-6B67-4F5F-9742-872FE033DC60Q38825084-9FE77C5E-9D79-4D29-A408-E247D94E2442Q38847011-7C12B074-1928-4A76-9F80-107A8C98A096Q39272947-B5616D21-47D6-40A3-9BA7-9C8D48DF5BDAQ39427133-13636985-8643-45EC-8E49-5C0F91DC7F77Q40090419-6FC7981B-4FE0-4747-A22F-6F1B8A9D8B5DQ40518124-E34FBB35-8E96-4BCD-A2A7-1DA1C7D7E5B1Q40815466-44633F0C-85B8-457D-836F-6437F0FDFA67Q41817333-4235DAE9-B160-4AC0-AAB4-175A886B81F9Q44249785-9805DF2D-B112-4F1B-ACA2-6E843BDB478CQ47314458-0A9ACDC7-728F-44B1-B33A-0754FC929553Q47691559-DD51A635-7E29-41EA-BCF4-318141482505Q47725075-38207D02-8ABE-4EDD-BEBF-F3663AA9EB89Q47758774-B939CC11-00F1-4EF9-AE69-204C365F2182Q47832169-FB14052E-3EB1-4E8E-BFCE-A2A8C1374E2AQ48134852-24BBEDCD-C9AA-449B-AB3A-D8D16682B5EEQ48229380-45116610-1353-4E7B-B8C7-7DA59BD749DFQ51163456-6DD6492C-1B59-445A-97F0-4F448C2C0457Q51397243-409C6200-0C8F-43F6-9D66-552664C7BF18
P2860
A review of methods for futility stopping based on conditional power.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
A review of methods for futility stopping based on conditional power.
@ast
A review of methods for futility stopping based on conditional power.
@en
type
label
A review of methods for futility stopping based on conditional power.
@ast
A review of methods for futility stopping based on conditional power.
@en
prefLabel
A review of methods for futility stopping based on conditional power.
@ast
A review of methods for futility stopping based on conditional power.
@en
P356
P1476
A review of methods for futility stopping based on conditional power.
@en
P304
P356
10.1002/SIM.2151
P407
P577
2005-09-01T00:00:00Z